+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 30 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating a nurse-led daily weight monitoring tool called Wake and Weigh to improve self-care and quality of life in older adults with heart failure. This pilot randomized controlled trial aims to test the feasibility and methods for a larger future study. The study focuses on adults aged 55 and older hospitalized with heart failure, addressing the challenges patients face with complicated self-care instructions and activity limitations. Participants are randomized to either use the Wake and Weigh tool along with usual care or receive usual care alone, which includes a heart failure handbook. The tool helps patients track their weight daily during hospitalization and after discharge, with nurse education and encouragement for consistent use. Patients record their weight each morning, using the same scale, and report significant weight changes to their healthcare provider. Follow-up calls occur at 2 weeks intervention group and 4 weeks both groups after discharge to assess tool use and health outcomes. During the study, participants complete surveys measuring heart failure self-care and quality of life at admission and 4 weeks post-discharge. Nurse investigators monitor the interventions delivery and patient use of the tool. Data collection includes hospital and follow-up visits, survey completion rates, and patient feedback on confidence and tool usefulness. The study lasts from hospital admission through 4 weeks after discharge, assessing feasibility, recruitment, retention, and appropriateness of the measurement tools.

Age: 55Years +All GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
R

Actively Recruiting

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

Age: 18Years +All GendersPhase 3
288 locations
R

Actively Recruiting

Researchers are evaluating the treatment of older adults aged 75 and above with early-stage cutaneous melanoma. The study compares the effectiveness of wide local excision WLE alone to the usual care of WLE combined with sentinel lymph node SLN biopsy. The main goal is to see if the less invasive WLE alone can provide similar results in preventing melanoma recurrence. This phase III trial also aims to assess patient-reported outcomes and the impact of geriatric assessments on treatment results. Participants are randomly assigned to one of two groups one group receives WLE plus SLN biopsy, and the other group receives WLE alone. Both groups may undergo surveillance of the lymph node area and receive additional treatments called adjuvant therapies if needed. Throughout the study, participants may have imaging tests such as computed tomography CT, positron emission tomography PETCT, or ultrasound. After initial treatment, patients are monitored closely with regular follow-ups. During the study, participants will be followed every four months for two years and then every six months up to five years after randomization. Researchers will collect data on recurrence-free survival, overall survival, melanoma-specific survival, safety, and patient quality of life. The study also involves comprehensive geriatric assessments and questionnaires to evaluate physical and functional status. These measures will help develop tools to predict risks and guide future surgical decisions for older adults with melanoma.

Age: 75Years +All GendersPhase 3
181 locations
P

Actively Recruiting

Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.

Age: 18Years +All GendersPhase 3
387 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
P

Actively Recruiting

Researchers are investigating whether adding the drug Docetaxel to the usual hormone treatments, Androgen Deprivation Therapy ADT and Androgen-Receptor Pathway Inhibitor ARPI, can better control metastatic castration sensitive prostate cancer in men who have not responded optimally to initial hormone therapy. This phase III, international, open-label, randomized trial seeks to compare the effectiveness of this combined approach against the standard hormone therapy alone. Participants will be randomly assigned to receive either the standard hormone therapy with ADT plus ARPI or the same hormone therapy combined with Docetaxel chemotherapy. The trial focuses on men with metastatic prostate cancer who continue to have elevated PSA levels after 6 to 12 months of hormone-targeting treatment. Treatments are administered according to physician choice and assignment, and the study evaluates outcomes over a long period. During the trial, participants will be closely monitored with assessments including PSA levels and clinical progression over 39 months. Researchers will measure overall survival as the primary outcome, along with secondary outcomes such as PSA progression, PSA response, PSA kinetics, and progression-free survival. Participants must be accessible for treatment and follow-up to allow for complete documentation of treatment effects and adverse events throughout the study duration.

Age: 18Years +MALEPhase 3
395 locations
C

Actively Recruiting

Researchers are studying patients with metastatic or unresectable dedifferentiated liposarcoma DDLPS, undifferentiated pleomorphic sarcoma UPS, or related poorly differentiated sarcomas to compare the effects of combining immunotherapy pembrolizumab with chemotherapy doxorubicin versus chemotherapy alone. The goal is to see if adding pembrolizumab helps patients live longer without their disease worsening. This is a phase III randomized trial focusing on treatment outcomes and safety. Participants are randomly assigned to one of two groups. One group receives doxorubicin intravenously every 21 days for six cycles along with pembrolizumab intravenously every 21 days for up to two years, provided there is no disease progression or unacceptable side effects. The other group receives only doxorubicin for six cycles and may receive pembrolizumab alone after disease progression, also given every 21 days for up to two years. Throughout the study, patients undergo heart function assessments ECHO or MUGA scans, standard imaging scans, and blood sample collections. During the trial, patients are monitored closely with scans and blood tests to assess disease progression and treatment effects. After completing treatment, follow-up visits occur every three months for two years and then every six months up to ten years. The main measure is progression-free survival, tracking the time until disease progression or death. Overall survival and response rates are also evaluated. Safety and tolerability are monitored throughout the study.

Age: 18Years +All GendersPhase 3
269 locations

1-10 of 30

1